Second-generation travoprost intracameral implant versus timolol drops for open-angle glaucoma
Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
This will test whether a small travoprost implant placed inside the eye can lower eye pressure as well as twice-daily timolol drops in people with open-angle glaucoma or ocular hypertension.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 510 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Glaukos Corporation Industry-sponsored |
| Locations | 1 site (Dothan, Alabama) |
| Trial ID | NCT07495852 on ClinicalTrials.gov |
What this trial studies
This Phase 3 interventional study compares a second-generation travoprost intracameral implant that releases medication inside the eye with timolol 0.5% eye drops given twice daily in people with open-angle glaucoma or ocular hypertension. The protocol includes implant and comparator arms as well as sham procedure and placebo drop components to support masking. The implant is delivered into the anterior chamber to provide sustained travoprost release while the comparator uses standard topical beta-blocker therapy. The trial focuses on safety and intraocular pressure lowering over the treatment period.
Who should consider this trial
Good fit: Adults with a diagnosis of open-angle glaucoma or ocular hypertension in the study eye who have not had prior incisional glaucoma surgery, argon laser trabeculoplasty, or minimally invasive glaucoma surgery in that eye.
Not a fit: Patients with prior incisional glaucoma surgery, prior ALT, or prior MIGS in the study eye (or those with glaucoma types other than open-angle) are not likely to be appropriate or to benefit from this protocol.
Why it matters
Potential benefit: If successful, the implant could provide sustained intraocular pressure control with less need for daily eye drop use.
How similar studies have performed: Earlier-generation intracameral travoprost implants have shown intraocular pressure–lowering effects in prior studies, while the second-generation device is a newer iteration undergoing Phase 3 confirmation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye
Where this trial is running
Dothan, Alabama
- Glaukos Investigative Site — Dothan, Alabama, United States (Recruiting)
Study contacts
- Study coordinator: Study Director
- Email: ClinicalResearch@glaukos.com
- Phone: 949-739-8749
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.